Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the
leading cause of cancer-related mortality worldwide. It is responsible for 80–85% of lung …

Introduction Most published guidelines for genomic biomarker testing in NSCLC reflect the
disease epidemiology and treatments readily available in Europe and North America …

Squamous cell carcinoma (SCC) comprises one of the major groups of non‐small‐cell
carcinoma of the lung, and is subtyped into keratinising, non‐keratinising and basaloid SCC …

The genomic origin and development of the biphasic lung adenosquamous carcinoma
(ASC) remain inconclusive. Here, we derived potential evolutionary trajectory of ASC …

Highlights•Complete and timely biomarker testing is crucial for selecting first-line systemic
therapy for patients with non-small-cell lung cancer.•Reflex testing is expeditious and …

Objective Panel-based next-generation sequencing (NGS) is increasingly used for the
diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk …

Aim: To estimate real-world (rw) outcomes for first-line therapy in patients with advanced
EGF receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), focusing on specific …

Precision oncology and immunotherapy have revolutionized the treatment of advanced non-
small-cell lung cancer (NSCLC). Emerging studies show that targeted therapies are also …

Introduction Molecular testing on advanced non–small cell lung cancer (NSCLC) often
confront of limited specimen. The aim of the study is to compare the mutation frequency in …

The role of the epidermal growth factor receptor (EGFR) mutation status testing in lung
squamous cell carcinoma (SqCC) remains controversial. Evidence of the effectiveness of …